LEO, MARENZA
 Distribuzione geografica
Continente #
NA - Nord America 1964
EU - Europa 829
AS - Asia 199
AF - Africa 16
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 3018
Nazione #
US - Stati Uniti d'America 1922
SE - Svezia 282
IT - Italia 145
CN - Cina 133
BG - Bulgaria 92
DE - Germania 85
GB - Regno Unito 66
AT - Austria 51
CA - Canada 42
FR - Francia 41
VN - Vietnam 28
FI - Finlandia 19
IN - India 16
UA - Ucraina 16
CI - Costa d'Avorio 14
BE - Belgio 13
TR - Turchia 13
RU - Federazione Russa 11
NL - Olanda 4
SG - Singapore 4
AU - Australia 3
EU - Europa 3
BR - Brasile 2
CH - Svizzera 2
HK - Hong Kong 2
RO - Romania 2
CL - Cile 1
DZ - Algeria 1
EC - Ecuador 1
JP - Giappone 1
PK - Pakistan 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 3018
Città #
Fairfield 288
Woodbridge 286
Houston 263
Ann Arbor 234
Chandler 158
Seattle 122
Ashburn 109
Wilmington 103
Sofia 92
Cambridge 85
Serra 66
Beijing 52
Vienna 50
Ottawa 37
Princeton 37
London 32
Lawrence 31
Medford 29
Bremen 26
Nanjing 24
Des Moines 23
Lancaster 23
Dong Ket 18
Dearborn 15
Marseille 15
Abidjan 14
Brussels 13
Frankfurt am Main 13
Nanchang 10
San Diego 10
Falls Church 9
Jacksonville 9
Hebei 8
Izmir 8
Chicago 7
Kunming 6
Pisa 6
Rome 6
Aosta 4
Changsha 4
Jüchen 4
Munich 4
Ossé 4
San Francisco 4
Singapore 4
Tianjin 4
Toronto 4
Boulder 3
Hangzhou 3
Jiaxing 3
Jinan 3
Ningbo 3
Redwood City 3
Abano Terme 2
Bucharest 2
Canberra 2
Chengdu 2
Düsseldorf 2
Egg 2
Englewood 2
Guangzhou 2
Gurgaon 2
Hefei 2
Kocaeli 2
Los Angeles 2
Milan 2
New Delhi 2
New York 2
Northbrook 2
Phoenix 2
Senigallia 2
Ambato 1
Auburn Hills 1
Boardman 1
Central District 1
Diss 1
Florence 1
Fuzhou 1
Grafing 1
Harran 1
Highland 1
Hyderabad 1
Islamabad 1
Kaohsiung 1
Lanzhou 1
Lishui 1
Mainz 1
Mascali 1
Melbourne 1
Norwalk 1
Palm City 1
Parma 1
Pomezia 1
Regensburg 1
Richmond 1
Santiago 1
Shanghai 1
Shenyang 1
Sovicille 1
Villasanta 1
Totale 2456
Nome #
Natural history of graves’ orbitopathy after treatment 156
A 70-year-old woman with Bilateral Orbital Infiltrative disease. 148
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy 140
Spontaneous improvement of untreated mild graves' ophthalmopathy: Rundle's curve revisited. 133
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 131
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 129
null 121
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 108
Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 102
Thyroid volume and severity of graves' orbitopathy 99
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 99
Dissecting the genetic susceptibility to graves' disease in a cohort of patients of Italian origin 99
null 97
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 97
null 93
Treatment options for Graves' orbitopathy. 92
null 91
PREGO ( presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 91
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 89
null 88
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 87
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 87
Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy 81
Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy 79
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial 72
Oxidative stress in graves' disease. 71
null 65
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 57
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 57
Hypothyroidism Due to L-T4 Withdrawal Can Precipitate Optic Neuropathy in Patients with Moderate to Severe Graves' Ophthalmopathy: Report on Two Cases 55
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy 49
Selenium in Graves Hyperthyroidism and Orbitopathy 46
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study 45
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy 19
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy 16
Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy 12
Total thyroid ablation in Graves' orbitopathy 2
Totale 3103
Categoria #
all - tutte 5077
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5077


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201835 0000 00 00 86156
2018/2019365 2052 89 636 24529995
2019/2020765 87438051 8686 8066 72415617
2020/2021286 14191930 3010 1929 26312039
2021/2022516 58638 11059 917 756311115
2022/2023546 641195451 4667 1458 73000
Totale 3103